Evaluation of immunohistochemically expression of GLUT-1 in benign proliferative, hyperplastic endometrium and endometriosis adenocarcinoma

Marwa Abdul Razak Jaleel, Sura Salman Ejam, Suhaila Fadhil Al-Shaikh
In: Iraq Medical Journal · 2022 · vol. 6(3) · doi:10.22317/imj.v6i3.1192 · W4308725697
Observational OA: gold CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-11-05 ⓘ

This study evaluated GLUT-1 expression in endometrial tissues, finding that immunostaining distinguishes hyperplasia with atypia from benign cases and is consistently overexpressed in endometrioid adenocarcinoma.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-10-09 · read from full text ⓘ

This cross-sectional study evaluated GLUT-1 expression in 98 endometrial tissue specimens, including benign proliferative, hyperplastic, and malignant tissues. The results indicated that GLUT-1 positivity was absent in benign proliferative and non-atypical hyperplasia but present in atypical hyperplasia and endometrioid adenocarcinoma. Consequently, the authors concluded that GLUT-1 immunostaining serves as a useful marker for distinguishing between hyperplasia with and without atypia. Relevance to endometriosis: listed as one of the tissue types analyzed alongside endometrial pathology, though the paper's main focus is endometrial hyperplasia and adenocarcinoma progression rather than endometriosis disease mechanisms.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Objectives: The aim of this study is to evaluate the GLUT-1 expression in benign proliferative, hyperplastic, and malignant endometrial tissues, to evaluate the usefulness of GLUT-1 expression in endometrial hyperplasia, and to determine its role in the neoplastic progression to endometrioid type adenocarcinoma. We also aimed to analyze some prognostic clinical parameters (age, stage, grade). Methods: This cross sectional study was carried out on paraffin embedded surgical specimens of endometrial tissue. Applying the immune histochemical techniques by using the GLUT-1 as a primary antibody, statistical analysis was done and the correlation with different clinical and pathological parameters were assessed. Results: 98 cases of endomertial tissue, 17.4% disordered proliferative endometrium, 22.4% endometrial hyperplasia without atypia, 18.4% endometrial hyperplasia with atypia, 41.8% endometrioid adenocarcinoma, 56.1% were GLUT-1 positive. Significant correlation was found between GLUT-1 expression and increasing degree of atypia as it was negative in benign proliferative and hyperplasia without atypia meanwhile positive in hyperplasia with atypia and endometrioid carcinoma. Significant correlation with grade of carcinoma, patient age, no correlation was found with ovarian and cervical metastasis, no significant correlation was found with tumor stage. Conclusions: GLUT-1 immunostaining may be useful in distinguishing hyperplasia without atypia from hyperplasia with atypia; GLUT-1 overexpression is a consistent feature of endometrioid adenocarcinoma.
Full text 2,063 characters · extracted from oa-doi-fallback · 4 sections · click to expand

Objectives

The aim of this study is to evaluate the GLUT-1 expression in benign proliferative, hyperplastic, and malignant endometrial tissues, to evaluate the usefulness of GLUT-1 expression in endometrial hyperplasia, and to determine its role in the neoplastic progression to endometrioid type adenocarcinoma. We also aimed to analyze some prognostic clinical parameters (age, stage, grade).

Methods

This cross sectional study was carried out on paraffin embedded surgical specimens of endometrial tissue. Applying the immune histochemical techniques by using the GLUT-1 as a primary antibody, statistical analysis was done and the correlation with different clinical and pathological parameters were assessed.

Results

98 cases of endomertial tissue, 17.4% disordered proliferative endometrium, 22.4% endometrial hyperplasia without atypia, 18.4% endometrial hyperplasia with atypia, 41.8% endometrioid adenocarcinoma, 56.1% were GLUT-1 positive. Significant correlation was found between GLUT-1 expression and increasing degree of atypia as it was negative in benign proliferative and hyperplasia without atypia meanwhile positive in hyperplasia with atypia and endometrioid carcinoma. Significant correlation with grade of carcinoma, patient age, no correlation was found with ovarian and cervical metastasis, no significant correlation was found with tumor stage.

Conclusions

GLUT-1 immunostaining may be useful in distinguishing hyperplasia without atypia from hyperplasia with atypia; GLUT-1 overexpression is a consistent feature of endometrioid adenocarcinoma. Downloads Published How to Cite Issue Section License Copyright (c) 2022 Iraq Medical Journal This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (20)

Source provenance

openalex
last seen: 2026-05-10T10:42:50.442627+00:00
License: CC0 · commercial use OK